With pivotal sepofarsen data due, the group will hope to get one up on Editas.
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.
But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.
Much of this week’s business development might be done and dusted, but for Biogen things are just warming up.
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.